©The Author(s) 2019.
World J Clin Oncol. Aug 24, 2019; 10(8): 283-292
Published online Aug 24, 2019. doi: 10.5306/wjco.v10.i8.283
Published online Aug 24, 2019. doi: 10.5306/wjco.v10.i8.283
Table 1 The clinical and treatment characteristics of the patients (n = 173)
| Characteristics | n (%) |
| AJCC 2010 T stage | |
| T1 | 3 (2) |
| T2a | 74 (43) |
| T2b | 14 (8) |
| T2c | 16 (9) |
| T3a | 49 (28) |
| T3b | 17 (10) |
| Gleason score (median) | 7 (3-9) |
| Initial PSA (median) | 14 ng/dL (2-100 ng/dL) |
| D’Amico risk group | |
| Intermediate | 52 (30) |
| High | 121 (70) |
| Perineural invasion | |
| Absent | 103 (60) |
| Present | 56 (32) |
| Unknown | 14 (8) |
| Percent positive core biopsy percentage | |
| ≤ 50 % | 76 (44) |
| > 50% | 59 (34) |
| Unknown | 38 (22) |
| Radiotherapy dose | |
| 736 Gy | 145 (84) |
| 76 Gy | 16 (16) |
- Citation: Ozyigit G, Hurmuz P, Yuce D, Akyol F. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. World J Clin Oncol 2019; 10(8): 283-292
- URL: https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i8.283